TransCode Therapeutics Inc. has announced the completion of its Phase 1a clinical trial evaluating TTX-MC138, an investigational inhibitor of microRNA-10b, in patients with metastatic disease. The trial met its primary safety endpoint and established a recommended Phase 2 dose. Sixteen patients were treated across four escalating dose levels, with no significant treatment-related safety events or dose-limiting toxicities observed. The median treatment duration was four months, ranging from two to twelve months, and three patients remain on trial. Preliminary data showed apparent stable disease lasting over four months in 44% of patients. Ongoing data analysis and monitoring are planned, with a final clinical study report, scientific presentations, and publications to be presented in the future. The company plans to advance TTX-MC138 into a Phase 2a clinical trial to further assess efficacy across selected metastatic diseases.